Skip to content

Effect of micuronium chloride on tonsillar adenoidectomy in pediatric patient :a prospective, randomized, controlled, double-blind clinical study

Effect of mivacurium on tonsillar adenoidectomy in pediatric patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075970
Enrollment
Unknown
Registered
2023-09-20
Start date
2023-10-01
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tonsillar adenoidectomy

Interventions

micuronium chloride group: micuronium chloride induction
Cis-atracurium :Cis-atracurium induction

Sponsors

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1) Sign informed consent; 2) Preschool children aged 3-6 years; 3) ASA grade I; 4) Subjects with tonsil adenoidectomy under quasi-general anesthesia; 5) Meet the weight standard:Weigh more than 13kg and less than 26kg;

Exclusion criteria

Exclusion criteria: 1) Difficult airway and severe respiratory diseases, acute respiratory infections, uncontrolled asthma and unexplained dyspnea; 2) Paediatric population requiring special care or supervision by courts/social welfare institutions; 3) Subjects with mental system diseases and cognitive dysfunction and a history of epilepsy; 4) Subjects with cardiovascular diseases (such as congenital heart disease, bradycardia requiring treatment, hypotension requiring treatment, etc.); 5) Subjects with abnormal liver function, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) exceeding 1.5 times the upper limit of normal; Subjects whose total bilirubin exceeds the upper limit of normal; Subjects with abnormal renal function and blood creatinine exceeding the upper limit of normal; 6) Abnormal plasma cholinesterase activity or pseudocholinesterase deficiency; 7) Participated in other clinical trials (received experimental drug or placebo) within 3 months before surgery; 8) Long-term use of drugs that affect muscle nerve conduction and allergic to narcotic drugs; 9) Other conditions deemed unsuitable for participation in this clinical trial by the investigator.

Design outcomes

Primary

MeasureTime frame
Muscle relaxation aging index;vital signs;

Secondary

MeasureTime frame
Adverse reaction;General information included age, sex, body mass index, and duration of surgery;

Countries

China

Contacts

Public ContactShangguan Wangning

Wenzhou Medical University Affiliated Stomatological Hospital

sgwning@163.com+86 135 8763 7891

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026